Evrysdi Seen to Improve Survival, Motor Development of Infants with SMA Type 1

Evrysdi Seen to Improve Survival, Motor Development of Infants with SMA Type 1

288357

Evrysdi Seen to Improve Survival, Motor Development of Infants with SMA Type 1

Genentech’s Evrysdi (risdiplam) improved survival in infants with spinal muscular atrophy (SMA) type 1, and allowed them to achieve developmental milestones not usually seen in the natural course of the disease, according to one-year data from the dose-finding part of the FIREFISH trial. While the trial is still ongoing and has moved to its confirmatory second part, these early findings were described in a study, titled “Risdiplam in Type 1 Spinal Muscular Atrophy,” published in…

You must be logged in to read/download the full post.